Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations
11 déc. 2020 07h00 HE
|
Prevail Therapeutics
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia
30 nov. 2020 07h00 HE
|
Prevail Therapeutics
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001
18 nov. 2020 19h02 HE
|
Prevail Therapeutics
NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
13 nov. 2020 07h00 HE
|
Prevail Therapeutics
Patient Dosing Continues in the Phase 1/2 PROPEL Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Phase 1/2 PROVIDE Trial of PR001 for Type 2 Gaucher Disease and Phase 1/2 PROCLAIM Trial of...
Prevail Therapeutics to Present at Upcoming Investor Conferences
10 nov. 2020 07h00 HE
|
Prevail Therapeutics
NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO
02 nov. 2020 07h00 HE
|
Prevail Therapeutics
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher Disease
27 oct. 2020 07h00 HE
|
Prevail Therapeutics
NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics to Present at Upcoming Investor Conferences
25 sept. 2020 17h21 HE
|
Prevail Therapeutics
NEW YORK, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
18 sept. 2020 15h04 HE
|
Prevail Therapeutics
NEW YORK, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Announces Appointment of William H. Carson, M.D., to Board of Directors
10 sept. 2020 07h00 HE
|
Prevail Therapeutics
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...